Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
Andreas Reiter, Juliana Schwaab, Daniel J. DeAngelo, et al.
Blood Advances (2022) Vol. 6, Iss. 21, pp. 5750-5762
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Avapritinib for advanced systemic mastocytosis
Jason Gotlib, Andreas Reiter, Daniel J. DeAngelo
Blood (2022) Vol. 140, Iss. 15, pp. 1667-1673
Closed Access | Times Cited: 27
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries
Johannes Lübke, Deborah Christen, Juliana Schwaab, et al.
Leukemia (2024) Vol. 38, Iss. 4, pp. 810-821
Open Access | Times Cited: 5
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms
Jason Gotlib
Hematology (2022) Vol. 2022, Iss. 1, pp. 34-46
Open Access | Times Cited: 20
World Health Organization Classification and Diagnosis of Mastocytosis
Peter Valent, Karl Sotlar, Hans‐Peter Horny, et al.
Immunology and Allergy Clinics of North America (2023) Vol. 43, Iss. 4, pp. 627-649
Closed Access | Times Cited: 11
Mastocytosis
Cem Akin, Michel Arock, Melody C. Carter, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access
Detecting Changes in Mast Cell Numbers Versus Activation in Human Disease: A Roadblock for Current Biomarkers?
Cem Akin, Frank Siebenhaar, Joshua B. Wechsler, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024) Vol. 12, Iss. 7, pp. 1727-1737
Open Access | Times Cited: 3
Mast cell disorders and Hymenoptera venom-triggered anaphylaxis: evaluation and management
Nathan A. Boggs, Ilaria Tanasi, Karin Hartmann, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024)
Closed Access | Times Cited: 3
A post‐marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database
Li Rong, Mengyuan Xie, Manxue Jiang, et al.
British Journal of Clinical Pharmacology (2023) Vol. 90, Iss. 8, pp. 1816-1826
Closed Access | Times Cited: 9
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis
Johannes Lübke, Nicole Naumann, Georgia Metzgeroth, et al.
Annals of Hematology (2023) Vol. 102, Iss. 8, pp. 2077-2085
Open Access | Times Cited: 8
Systemic mastocytosis: 2023 update on diagnosis and management in adults
Alessandro Nanni Costa, Emilia Scalzulli, Ida Carmosino, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 3, pp. 153-165
Closed Access | Times Cited: 7
Clinical and Therapeutic Intervention of Hypereosinophilia in the Era of Molecular Diagnosis
Lynh Nguyen, Aditi Saha, Andrew Kuykendall, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1383-1383
Open Access | Times Cited: 2
Cost of Drug Wastage From Dose Modification and Discontinuation of Oral Anticancer Drugs
Michael S. Lam, Timothée Olivier, Alyson Haslam, et al.
JAMA Oncology (2023) Vol. 9, Iss. 9, pp. 1238-1238
Open Access | Times Cited: 5
Recent advances in diagnosis and therapy in systemic mastocytosis
Hyun Jung Lee
Blood Research (2023) Vol. 58, Iss. S1, pp. S96-S108
Open Access | Times Cited: 4
Detection of KIT Mutations in Systemic Mastocytosis: How, When, and Why
Daniela Cilloni, Beatrice Maffeo, Arianna Savi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 20, pp. 10885-10885
Open Access | Times Cited: 1
Eosinophilia in a patient with aggressive systemic mastocytosis harboring a KIT D816V mutation: A case report
Lihong Cao, Hongyan Tong, Xing Liu, et al.
SAGE Open Medical Case Reports (2023) Vol. 11
Open Access | Times Cited: 2
Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
Peter Valent, Cem Akin, Michel Arock, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15125-15125
Open Access | Times Cited: 2
Evaluation of Bioequivalence for Avapritinib Tablets in Chinese Participants Under Fasting Conditions Using a Reference‐Scaled Average Bioequivalence Method
Zenglian Yue, Yin Wang, Li Zeng, et al.
Clinical Pharmacology in Drug Development (2024) Vol. 13, Iss. 6, pp. 672-676
Closed Access
Лечение агрессивного системного мастоцитоза и тучноклеточного лейкоза. Обзор литературы и серия клинических наблюдений
В. Г. Потапенко, З. К. Абдулхаликова, В В Байков, et al.
Clinical oncohematology (2024) Vol. 17, Iss. 2, pp. 180-194
Open Access
Mastocytosis—a frequently unrecognized disease
Melba Muñoz, Frank Siebenhaar
best practice onkologie (2024) Vol. 19, Iss. 5, pp. 206-217
Closed Access
SOHO State of the Art Update and Next Questions: Current and Emerging Therapies for Systemic Mastocytosis
Helen T. Chifotides, Prithviraj Bose
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access
Comparison of prognostic scores according to WHO classification in 170 patients with advanced mastocytosis and C‐finding treated with midostaurin
Maël Heiblig, C. Gourguechon, Philippe Guilpain, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 11, pp. 2127-2139
Open Access
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis
Francesco Mannelli, Francesca Crupi, Roberta Zanotti, et al.
Therapeutic Advances in Hematology (2023) Vol. 14
Open Access | Times Cited: 1
Mastocytosis—a frequently unrecognized disease
Melba Muñoz, Frank Siebenhaar
Deleted Journal (2023)
Closed Access | Times Cited: 1
Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms
Tsewang Tashi, Michael W. Deininger
Immunology and Allergy Clinics of North America (2023) Vol. 43, Iss. 4, pp. 723-741
Closed Access
Successful treatment of systemic mastocytosis with acute myeloid leukemia: a case report
Minran Zhou, Guangcai Zhong, Yuan Yu, et al.
Annals of Hematology (2023) Vol. 102, Iss. 10, pp. 2951-2953
Closed Access
Page 1 - Next Page

Scroll to top